Evidence map›Paper›PMID 26605644›Full record

ReviewMolecular medicine (Cambridge, Mass.)2015

Detection and Clinical Significance of Circulating Tumor Cells in Colorectal Cancer--20 Years of Progress.

Jennifer E Hardingham, Phulwinder Grover, Marnie Winter, Peter J Hewett, Timothy J Price, Benjamin Thierry

Open access · goldAbstract readHistorical ArticleReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular medicine (Cambridge, Mass.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed
6.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 137 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Jennifer E HardinghamMolecular Oncology Group, Haematology-Oncology Department, Basil Hetzel Institute, The Queen Elizabeth Hospital, Woodville, South Australia.
Phulwinder GroverDepartment of Surgery, The Queen Elizabeth Hospital, Woodville, South Australia.
Marnie WinterIan Wark Research Institute, University of South Australia, Mawson Lakes, South Australia.
Peter J HewettDepartment of Surgery, The Queen Elizabeth Hospital, Woodville, South Australia.
Timothy J PriceSchool of Medicine, University of Adelaide, South Australia.
Benjamin ThierryIan Wark Research Institute, University of South Australia, Mawson Lakes, South Australia.
Queen Elizabeth Hospital · AUUniversity of South Australia · AUBasil Hetzel Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Circulating tumor cells (CTC) may be defined as tumor- or metastasis-derived cells that are present in the bloodstream. The CTC pool in colorectal cancer (CRC) patients may include not only epithelial tumor cells, but also tumor cells undergoing epithelial-mesenchymal transition (EMT) and tumor stem cells. A significant number of patients diagnosed with early stage CRC subsequently relapse with recurrent or metastatic disease despite undergoing "curative" resection of their primary tumor. This suggests that an occult metastatic disease process was already underway, with viable tumor cells being shed from the primary tumor site, at least some of which have proliferative and metastatic potential and the ability to survive in the bloodstream. Such tumor cells are considered to be responsible for disease relapse in these patients. Their detection in peripheral blood at the time of diagnosis or after resection of the primary tumor may identify those early-stage patients who are at risk of developing recurrent or metastatic disease and who would benefit from adjuvant therapy. CTC may also be a useful adjunct to radiological assessment of tumor response to therapy. Over the last 20 years many approaches have been developed for the isolation and characterization of CTC. However, none of these methods can be considered the gold standard for detection of the entire pool of CTC. Recently our group has developed novel unbiased inertial microfluidics to enrich for CTC, followed by identification of CTC by imaging flow cytometry. Here, we provide a review of progress on CTC detection and clinical significance over the last 20 years.

Indexed as

Basic Helix-Loop-Helix ProteinsBiomarkersCell SeparationColorectal NeoplasmsEpithelial CellsEpithelial-Mesenchymal TransitionGene ExpressionGranulocyte Colony-Stimulating FactorHistory, 20th CenturyHistory, 21st CenturyHumansMicrofluidicsNeoplastic Cells, CirculatingNeoplastic Stem CellsPrognosisReceptors, G-Protein-CoupledASCL2 protein, humanBasic Helix-Loop-Helix ProteinsBiomarkersGranulocyte Colony-Stimulating FactorLGR5 protein, humanOLFM4 protein, humanReceptors, G-Protein-Coupled

Identifiers

PMID26605644
PMCPMC4661051
OpenAlexW2407632247

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.